SPIA
RNAM

Steward Partners Investment Advisory’s Avidity Biosciences RNAM Stock Holding History

Steward Partners Investment Advisory’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,626
Closed -$550K – 4541
2025
Q4 		$550K Sell
7,626
-21,714
-74% -$1.4M ﹤0.01% 1370
2025
Q3 		$1.28M Buy
29,340
+7,157
+32% +$289K 0.01% 948
2025
Q2 		$630K Sell
22,183
-24,567
-53% -$732K ﹤0.01% 1189
2025
Q1 		$1.38M Sell
46,750
-1,700
-4% -$52.9K 0.01% 791
2024
Q4 		$1.41M Sell
48,450
-45,168
-48% -$1.89M 0.01% 745
2024
Q3 		$4.3M Sell
93,618
-9,582
-9% -$416K 0.04% 403
2024
Q2 		$4.22M Buy
103,200
+2,700
+3% +$77.5K 0.04% 368
2024
Q1 		$2.56M Buy
100,500
+41,500
+70% +$650K 0.03% 503
2023
Q4 		$534K Buy
59,000
+39,500
+203% +$264K 0.01% 970
2023
Q3 		$124K Buy
19,500
+16,500
+550% +$142K ﹤0.01% 1477
2023
Q2 		$33.3K Buy
+3,000
New +$37.6K ﹤0.01% 2053
2021
Q2 		– Sell
-150
Closed -$3.27K – 7348
2021
Q1 		$3.27K Buy
+150
New +$3.67K ﹤0.01% 3113

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

Steward Partners Investment Advisory's RNAM Position: Q1 2026 in Review

Steward Partners Investment Advisory sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 7,626 shares — an estimated $550K sold.

Steward Partners Investment Advisory first reported a position in RNAM in Q1 2021 and held it in 12 quarters. The position peaked at $4.3M in Q3 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Steward Partners Investment Advisory reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 7,626 Avidity Biosciences shares in Q1 2026, an estimated $550K.
  • Steward Partners Investment Advisory first reported a position in Avidity Biosciences in Q1 2021 and held it in 12 quarters.
  • Steward Partners Investment Advisory's Avidity Biosciences position peaked at $4.3M in Q3 2024.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.